ZYME
Zymeworks Inc.
stockNASDAQ
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company's novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 27.12 | 2026-09-28 | -7.28% | -2.051 |
| 1M | 29.19 | 2026-09-04 | -13.86% | 0.955 |
| 3M | 25.33 | 2026-07-06 | -0.73% | 0.933 |
| 6M | 25.84 | 2026-04-06 | -2.69% | 0.782 |
| 1Y | 16.69 | 2025-10-06 | +50.70% | 0.647 |
| 2Y | 12.57 | 2024-10-04 | +100.04% | — |
| 5Y | 28.08 | 2021-10-05 | -10.45% | 0.900 |
Zymeworks Inc. (NASDAQ:ZYME) stock price today is $25.15, and today's volume is 844,446. ZYME is down 3.139% today. The 30 day average volume is 845,529. ZYME market cap is $1.80B with 71.75M shares outstanding.